Adverse Event Reporting

VAERS ID 2594333
Gender Male
Age
StateCode CA
Pharmaceutical Company PFIZER\BIONTECH
Lot Number
Number of vaccinations
Vaccinated
Onset
Condition
Symptoms

Current Illness

Preexisting Conditions

Other Medications

DUPIXENT

Previous Vaccinations

Allergies

Laboratory Data

Write-up

autoimmune reaction; Eczema; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).
Other Case identifier(s): 2023SA040901.
A 92-year-old male patient received BNT162b2 (BNT162B2), in 2022 as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation; dupilumab (DUPIXENT), (Batch/Lot number: unknown) at first dose.
The patient's relevant medical history and concomitant medications were not reported.
Vaccination history included: Bnt162b2 (Dose number unknown, manufacturer unknown), administration date: 2022, for Covid-19 immunisation.
The following information was reported: AUTOIMMUNE DISORDER (medically significant), outcome "unknown", described as "autoimmune reaction"; ECZEMA (medically significant), outcome "unknown".
It was reported that "he believes his eczema is due to an autoimmune reaction from receiving the Pfizer Covid Vaccine regimen.
He received two doses of the vaccine back in early 2022.
No lab data was reported.
" The action taken for dupilumab was unknown.
Case was assessed as not serious and Company agent (Private) casual was Yes.
No follow-up attempts are needed; information about lot/batch number cannot be obtained.
No further information is expected.